AzTrials
AzTrials

Mild Cognitive ImpairmentCOMETNCT05332522

Computerized Memory Enhancing Treatment in MCI

A study testing Neuroplasticity-based Computerized Cognitive Remediation in people with Mild Cognitive Impairment, run by Vanderbilt University Medical Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The investigators propose to apply neuroplasticity-based computerized cognitive remediation (nCCR) to improve memory function in patients with Mild Cognitive Impairment (MCI). Read more about this study

Who is it for?
Ages 55 to 85 years
Conditions the study is for
Mild Cognitive Impairment
What is being tested?
Neuroplasticity-based Computerized Cognitive Remediation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
19 participants
Where
1 siteUnited States
Study dates
9 Aug 2022to 31 Dec 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 55 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Have a subjective memory concern as reported by participant, study partner or clinician
  • Be between 55 and 85 years of age (inclusive)
  • Clinical Dementia Rating16 Global score of 0.5
  • Mini-Mental State Exam score between 22-30 (inclusive)
  • General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer's disease dementia cannot be made by the site clinician at the time of the screening visit
  • Geriatric Depression Scale score of less than or equal to 14
Show all 11Show fewer
  • Study Partner is available who has frequent contact with the participant (e.g. an average of 10 hours per week or more), and can accompany the participant to most visits to answer questions about the participant
  • Adequate visual and auditory acuity to allow neuropsychological testing
  • Good general health with no additional diseases/disorders expected to interfere with the study
  • Participant is not pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal or surgically sterile)
  • Completed six grades of education or has a good work history Fluent in and able to read English.

Who cannot join

  • Any significant neurologic disease such as Alzheimer's disease dementia, Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities.
  • Major depression, bipolar disorder as described in DSM-V within the past 1 year or psychotic features, agitation or behavioral problems within 3 months, which could lead to difficulty complying with the protocol
  • History of schizophrenia (DSM V criteria)
  • History of alcohol or substance abuse or dependence within the past 2 years (DSM V criteria)
  • Clinically significant or unstable medical condition, including uncontrolled hypertension, uncontrolled diabetes, or significant cardiac, pulmonary, renal, hepatic, endocrine, or other systemic diseases in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results, or the participant's ability to participate in the study.
  • Has had a history within the last 5 years of a primary or recurrent malignant disease with the exception of non-melanoma skin cancers, resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with normal prostate-specific antigen post-treatment
Show all 9Show fewer
  • Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening,
  • Residence in a skilled nursing facility
  • Participants whom the Principal Investigator deems to be otherwise ineligible.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37212

Other trials in United States

About this study

Official title: A Pilot and Feasibility Study of Computerized Cognitive Remediation to Improve Cognitive and Functional Performance in Adults With Mild Cognitive Impairment

The investigators propose to apply neuroplasticity-based computerized cognitive remediation (nCCR) to improve memory function in patients with Mild Cognitive Impairment (MCI).

Read the detailed description

There is currently no efficacious treatment to delay or prevent decline from mild cognitive impairment (MCI) to dementia. Despite major technological advances, from refined animal models, novel molecular approaches, and in vivo biological marker development, discoveries have not translated into effective treatments to prevent decline. A potential alternative approach is cognitive training, however previous studies on memory-focused training have had mixed success in MCI groups, and longer-term improvement has not been observed. A more effective strategy may be to target the deterioration of networks that support memory function, for instance the frontoparietal cortical regions of the cognitive control network (CCN) which are important for higher-order cognitive functions such as planning and switching effectively. These networks become increasingly vital during aging and cognitive decline, as frontal lobe activation acts as a compensatory mechanism for lower-level structural deficits. The present study proposes a novel cognitive enhancement strategy, informed by clinical, behavioral, and neurobiological data suggesting that strengthening these frontal area connections in the CCN may compensate for the deficits in circuitry associated with MCI.

Neuroplasticity-based computerized cognitive remediation (nCCR) is a cognitive enhancement strategy that aims to alter disease-related changes in brain function through the induction of neuroplasticity in clinically relevant networks, subsequently resulting in improved cognitive performance. Neuroplasticity refers to the brain's ability to modify, change, and adapt both structure and function and can be induced through the use of network-specific techniques expressed even in the abnormally aging brain. nCCR involves an intensive, attention-demanding schedule of computerized cognitive training that is both individually adaptive and rewarding to participants. nCCR uses bottom-up and top-down training strategies that have been proven in both preclinical and clinical models to induce neuroplasticity and cognitive enhancement. "Bottom-up" perceptual training in both animal models and older adults has been observed to improve both targeted (perceptual discrimination) and other cognitive functions (working memory). "Top-down" activation of the CCN via nCCR has been shown to improve targeted functions (cognitive flexibility), and also to transfer this improvement to other, untrained skills (episodic memory) in older adults. Prior studies in late-life depression show that nCCR can transfer improvements from targeted to untrained processes, which may lead to a functional improvement in multiple cognitive domains. The researchers propose to test whether in MCI patients, boosting CCN activation may produce enhancement to deficits that are characteristic of the syndrome such as memory and attention.

The proposed study utilizes an nCCR intervention strategy which has successfully shown reductions in executive dysfunction in adults with geriatric depression, and recently been applied by our group to participants suffering from chemotherapy-related cognitive impairment (CRCI) with promising preliminary results showing improvements in both subjective ratings of performance and objective cognitive performance. The proposed study aims to use this nCCR intervention to examine the potential benefits in MCI patients and to obtain pilot data for a larger randomized clinical trial. Before and after the treatment period the researchers will examine self-report and objective measures of performance and utilize EEG to assess physiological changes associated with neuroplasticity induced by nCCR treatment.

Being tested
Neuroplasticity-based Computerized Cognitive Remediation
Keywords
nCCR, MCI, Mild Cognitive Impairment, Neuroplasticity-based computerized cognitive remediation
Medical subject headings
Cognitive Dysfunction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Neuroplasticity-based Computerized Cognitive RemediationBehavioural

    The nCCR has two major components: Bottom up and Top down training.

    Bottom up" training: The training includes selected tasks from "Brain HQ", a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.

    Top down training": We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These "Top Down" Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization.

Study groups in NCT05332522
Study groupRoleWhat they receive
Neuroplasticity-based Computerized Cognitive RemediationExperimentalParticipants will receive a 45-hour of Neuroplasticity-based Computerized Cognitive Remediation
Receives: Behavioral: Neuroplasticity-based Computerized Cognitive Remediation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluate completion rates of nCCR

    Assess the percentage of enrolled participants who completed of the 40-hour nCCR treatment.

    Measured: 2 years

  2. Evaluate visit frequency throughout nCCR treatment

    Assess the frequency of visits during nCCR treatment

    Measured: Through study completion, an average of 6 weeks.

  3. Evaluate visit duration throughout nCCR treatment

    Assess the duration of visits during nCCR treatment

    Measured: Through study completion, an average of 6 weeks.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Apr 2022
  2. Study start9 Aug 2022
  3. Primary completion31 Jul 2024
  4. Study completion31 Dec 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Single Group Assignment A single-arm, open label design; All analyses are pre-post, with participants serving as their own controls.
Masking
None (open label)
Enrolment
19 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05332522
Sponsor's protocol ID
212375
Acronym
COMET
Status last verified
Feb 2025
First submitted
8 Apr 2022
Last updated
11 Feb 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Neuroplasticity-based Computerized Cognitive Remediation in people with Mild Cognitive Impairment, run by Vanderbilt University Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluate completion rates of nCCR (time frame: 2 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in